Tirzepatide

Dual GIP/GLP-1 receptor agonist. Mounjaro / Zepbound. More potent fat loss than Semaglutide in clinical trials. Increasingly popular in bodybuilding for cutting.

Overview

GLP-1

Dual GIP/GLP-1 receptor agonist. Mounjaro / Zepbound. More potent fat loss than Semaglutide in clinical trials. Increasingly popular in bodybuilding for cutting.

Effects on Markers

Significant appetite suppression, improves fasting glucose and HbA1c (more potently than Semaglutide), improves lipid profile, may mildly affect liver enzymes (typically improvement), can elevate amylase/lipase, reduces CRP and inflammatory markers

Compound Guide

Structure: Dual-acting peptide — agonist at both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptors. The dual mechanism provides more potent metabolic effects than GLP-1 alone.

Dosage:

  • Weight loss (titrate up): 2.5mg/week x4 weeks → 5mg/week x4 weeks → 7.5mg/week → 10mg/week → 12.5mg/week → 15mg/week
  • Bodybuilding cut: 5-10mg/week (titrate based on appetite suppression and tolerability)

Administration:

  • SubQ injection once weekly, abdomen/thigh/upper arm
  • Titrate slowly — at least 4 weeks at each dose level to minimise GI sides

Key Notes:

  • Clinical trials show greater weight loss than Semaglutide at maximal doses
  • Same GI side effect profile as Semaglutide but can be more pronounced during titration
  • Dual GIP/GLP-1 mechanism may better preserve muscle mass compared to GLP-1-only agonists (emerging data)
  • Extremely potent appetite suppression — some users struggle to eat enough protein
  • Maintain resistance training and high protein intake (>2g/kg) to preserve muscle
  • Monitor: fasting glucose, HbA1c, lipid panel, amylase/lipase, liver enzymes
  • Same pancreatitis risk considerations as Semaglutide

Usage History

Markers to Monitor

Frequently Asked Questions

Quick Reference

Category

GLP-1

Half-Life

5 days

Detection Time

N/A

Usage Summary